Topiramate (Epilepsy)

ADHD (Attention deficit hyperactivity disorder): Diagnosis/Risk

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S15875
R65447		 Dreier (Topiramate) (Epilepsy) (Controls exposed to LTG), 2023 Attention-deficit/hyperactivity disorder (ADHD) - Corresponding ICD-10 F-chapter - Up to 22 years of age during pregnancy (anytime or not specified) population based cohort propective exposed to other treatment, sick excluded Adjustment: No 3.19 [1.85;5.50] C
excluded (control group) 		16/290   95/5,288 111 290
ref
S15876
R65456		 Dreier (Topiramate) (Epilepsy) (Controls unexposed, sick), 2023 Attention-deficit/hyperactivity disorder (ADHD) - Corresponding ICD-10 F-chapter - Up to 22 years of age during pregnancy (anytime or not specified) population based cohort propective unexposed, sick Adjustment: Yes 2.38 [1.40;4.06] 16/290   528/22,203 544 290
ref
S7307
R48831		 Bromley (Topiramate), 2016 Maladaptive behavior: Attention (BASC) (5-9 years old) during pregnancy (anytime or not specified) retrospective cohort (registry) unexposed, sick Adjustment: No extrapolated (cont. endpoint) 1.00 [0.43;2.31] -/27   -/55 - 27
ref
Total 2 studies 1.64 [0.71;3.81] 544 317
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Dreier (Topiramate) (Epilepsy) (Controls unexposed, sick), 2023Dreier, 2023 1 2.38[1.40; 4.06]54429057%ROB confusion: seriousROB selection: lowROB classification: moderateROB missing: lowROB mesure: criticalROB reporting: moderate Bromley (Topiramate), 2016Bromley, 2016 2 1.00[0.43; 2.31]-2743%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Total (2 studies) I2 = 66% 1.64[0.71; 3.81]5443170.55.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Topiramate) (Epilepsy) (Controls unexposed, sick; 2: Topiramate;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 1.64[0.71; 3.81]54431766%NADreier (Topiramate) (Epilepsy) (Controls unexposed, sick), 2023 Bromley (Topiramate), 2016 2 case control studiescase control studies 0 Type of controls unexposed, sickunexposed, sick 1.64[0.71; 3.81]54431766%NADreier (Topiramate) (Epilepsy) (Controls unexposed, sick), 2023 Bromley (Topiramate), 2016 2 Tags Adjustment   - No  - No 1.00[0.43; 2.32]-27 -NABromley (Topiramate), 2016 1   - Yes  - Yes 2.38[1.40; 4.05]544290 -NADreier (Topiramate) (Epilepsy) (Controls unexposed, sick), 2023 1 extrapolated (cont. endpoint)extrapolated (cont. endpoint) 1.00[0.43; 2.32]-27 -NABromley (Topiramate), 2016 1 All studiesAll studies 1.64[0.71; 3.81]54431766%NADreier (Topiramate) (Epilepsy) (Controls unexposed, sick), 2023 Bromley (Topiramate), 2016 20.55.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded 15875

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed, sick controlsunexposed, sick controls 1.64[0.71; 3.81]54431766%NADreier (Topiramate) (Epilepsy) (Controls unexposed, sick), 2023 Bromley (Topiramate), 2016 2 exposed to other treatment, sick controlsexposed to other treatment, sick controls 3.19[1.85; 5.50]111290 -NADreier (Topiramate) (Epilepsy) (Controls exposed to LTG), 2023 10.510.01.0